GENENTECH, a member of the Roche Group, received a second Breakthrough Therapy Designation from FDA for its anaplastic lymphoma kinase inhibitor, Alecensa (alectinib). The latest BTD was granted for the treatment of adult patients with advanced ALK-positive non-small cell lung cancer who have not received prior treatment with an ALK inhibitor.
Genentech receives second Breakthrough Therapy Designation from FDA for Alecensa
YOU MAY BE INTERESTED IN
The National Coalition for Cancer Survivorship has provided the Cancer History Project with a rich archive of its newsletters: the NCCS Networker, volumes 1-11.